Theratechnologies Inc T.TH

Piper Sandler Conf?

[Wino115]

Anyone listen in on THTX at the conf either yesterday or today? Maybe THTX will post a link.  Will be interesting to hear if they continue to evolve positively in how they talk about the pipeline. Practice makes perfect in that regard. Not sure we'll hear anything new, but just wanted to know if anyone listened in and picked up anything.

[qwerty22]

It happened a week ago, you listened to it.  

[StableGenius97]

MONTREAL, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that some of its management team members will be participating in the upcoming Piper Sandler 32 nd Annual Virtual Healthcare Conference on December 1 and 2

[jfm1330]

I just listened to it. Nothing new, but Levesque is very good at explaining why he believe in the NASH trial and also in the oncology program. He is very upbeat about the oncology, it could be massive. He said submission of the NASH protocol to the FDA is imminent.

[Wino115]

I may be wrong but had thought that Fireside Chat with the analyst was a soft intro video and then there was an actual conference slot yesterday or today that was more detailed and maybe Q and A.     Not really sure though as I haven't seen any schedule for the conf.  

[qwerty22]

I think you're right sorry

[SPCEO1]

The Piper conference turned out to be one on one meetings with portfolio managers on 12/1 and 12/2 and the Fireside Chat was the "presentation".  

[Wino115]

I guess you had no reason to take a slot from someone else.  Hear any feedback, anything new?  Maybe the analyst will write up one of those Conf Notes kind of things in the next week. I"m guessing it may have been Dubuc who did these since they just said "management" would present and not CEO specifically.  Maybe Marsolais. Hope they have refined the message and flow

[SPCEO1]

I did not take an official slot but did speak with Leah Gibson during her lunch break fom other meetings. There was nothing all that new from that relatively short conversation. I hope to catch up with her again soon. She reiterated they were not planning to put out a PR on the submission of the NASH phase III protocol. She said if they put out some related PR maybe they would slide some mention

[scarlet1967]

"She said if they put out some related PR maybe they would slide some mention of it into it but that they did not want to set a precedent for PR'ing a non-material piece of info like that. Basically, they don't want to become CYDY." Why the submission is not a material event specially when there has been many doubts re validity of the program and delays? They don't need to

[Wino115]

I understand your point Scarlet. I guess a "submission", which they've already flagged, is not really a "material" even in the legal sense since you could submit whatever you want.  The material event for the drug development pathway is the approval I suppose. Actually, what's odd is it's not an "approval", it's a "no comments", meaning

[SPCEO1]

TH is adhering to the approach most drug company's take in not considering a submission of a trial protocol a material event. So, that is not an unusual approach. CYDY has the unusual approach of PR'ing everything almost to including when the CEO most recently trimmed his toenails! The submission of the protocol is not a material event because it means nothing until the FDA/EMA say "

[qwerty22]

It would be nice to test the proposition that they CAN build expectation. I think I could forgive them for doing it once!  Haven't all the recent investor conferences been about building expectations? Having said that I think you are about right, it's less common to announce that step, Maybe it happens more in going from pre-clinical to clinical, in some senses we are doing

[SPCEO1]

I have not had that conversation withher recently but she did note one time we spoke that she told TH before she joined that it takes a fair amount of time to build a good IR operation and that they should be prepared for a lot of spade work before reaping the fruits of those labors. And that is true. My hope is we will start seeing those benefits soon. If the FDA gets on board with what TH is

[qwerty22]

That second point you get from your own intuition or your interpretation of noises made by the company? That's exciting to hear because it fits my own expectation ( nothing better than confirmation bias!). I think there's going to be value in that both for us and the company, and maybe it'll satisfy some of the analysts misgivings. I'm of the opinion once you've fully accounted

[Wino115]

Let's not forget the bullish point made many times here -- that so far the FDA and EMA are seeing compounds fall by the wayside as either completely ineffective (many) or not particularly safe given the patient condition (a few, and likely more as time goes by).  The list grows of those in need of transplants, those with NAFLD moving into NASH and there's nothing out there.  I

[scarlet1967]

That is correct and the strength of THTX's program, the genomic aspect of treatments for many conditions is evolving and getting more attention. https://www.e-cmh.org/m/journal/view.php?doi=10.3350/cmh.2020.0136

[scarlet1967]

"Abstract Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary

[SPCEO1]

I did not get that from the company as they are pretty adamant about the phase III being all that is needed, as you would expect them to be at this point. There is certainly a case for that but based on your past comments on the subject and the Canaccord analyst's assumption of a phase IIb/III, as well as just a bit of common sense, I believe the FDA will want them to do something to firm up